Previous studies by our group and others have shown that treatment with MIA-602 and MIA-690 suppresses tumoral IGF1 expression in mouse models of human cancers without significantly altering serum GH levels, further supporting the GH-independent actions of these peptides [18,22,41]. Here, IGF1 is linked to cancer.